|Targets||Akt | ERK | Trk Receptor|
|Description||LM22B-10 is an activator of TrkB/TrkC neurotrophin receptor, which activates hippocampal and striatal TrkB and TrkC, and their downstream signaling, and increased hippocampal dendritic spine density.|
|Solubility||DMSO: ≥ 150 mg/mL|
|Storage||Store in a cool and dry place (or refer to the Certificate of Analysis).|
|Boiling Point||718.9±60.0 ℃ at 760 Torr|
Uprosertib, also known as GSK2141795 and GSK795, is an orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potentia...
This active molecular is a selective pan-TRK inhibitor. GNE-8525 shows potent antiproliferation activity (IC50 = 0.003 μM) and it shows in vivo antitumor effica...
Ipatasertib, also known as GDC-0068 is an orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplas...
Belizatinib is inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinases (TRK). Belizatinib can bind to and inhibit both ALK and TRK ki...
SC79 is a brain-penetrable Akt phosphorylation activator and an inhibitor of Akt-PH domain translocation.
TIC10 inactivates Akt and ERK to induce TRAIL through Foxo3a, possesses superior drug properties: delivery across the blood-brain barrier, superior stability an...
Ulixertinib, also known as BVD-523 and VRT752271 is a potent and reversible ERK1/ERK2 inhibitor with IC50 of <0.3 nM for ERK2. Upon oral administration, BVD-523...
GDC-0994, also known as RG7842, is an orally available inhibitor of extracellular signal-regulated kinase (ERK), with potential antineoplastic activity. Upon or...
GW 441756 is a potent and selective Tropomyosin-related kinase A (TrkA) inhibitor (IC50 = 2 nM), reducing cell proliferation and potentiates the effects of chem...
GSK2110183 is an orally bioavailable pan-Akt inhibitor with IC50s of 0.08/2/2.6 nM for Akt1/Akt2/Akt3 respectively.
AKT Kinase Inhibitor
AKT Kinase Inhibitor is a Akt Kinase Inhibitor.
LM22B-10 is an activator of TrkB/TrkC neurotrophin receptor, which activates hippocampal and striatal TrkB and TrkC, and their downstream signaling, and increas...
Tavilermide is a selective, small-molecule partial agonist of TrkA, or a nerve growth factor (NGF) mimetic.
VX-11e is a potent, selective, and orally bioavailable inhibitor of ERK, which is extracellular signal-regulated kinases. It is an antitumor agent and potently ...
TPX-0005 is an orally available and potent ATP-competitive inhibitor of ALK/ROS1/TRK (IC50= 5.3 nM for SRC, IC50= 1.01 nM, 1.26 nM and 1.08 nM for mutant ALKs i...
Corynoxeine is a potent ERK1/2 inhibitor of key PDGF-BB-induced VSMC proliferation and a useful and prospective compound in the prevention and treatment for vas...
Potent and selective ERK5 inhibitor; inhibits EGFR-induced ERK5 autophosphorylation (EC50 = 90 nM) and ERK5 enzymatic activity (IC50 = 162 nM). Exhibits at leas...
Testing against a broad panel of 230 kinases, GDC-0068 only inhibits 3 kinases by >70% at 1 μM concentration (PRKG1α, PRKG1β, and p70S6K, with IC50 of 98 nM, 69...
The sulfate salt form of LOXO-101, also called Larotrectinib, is a ATP-competitive inhibitor of tropomyosin receptor kinases and is still under Phase II clinica...
CCT128930 is a novel ATP-competitive AKT inhibitor discovered using fragment- and structure-based approaches. It is a potent, advanced lead pyrrolopyrimidine co...